-
17Transparency Is Not Enough: structural Risks in the Normalization of Growth Attenuation TherapyAmerican Journal of Bioethics 26 (6): 101-104. 2026.Since the controversy surrounding the Ashley case in 2006, Growth Attenuation Therapy (GAT) has remained the subject of sustained and intense debate. Yet despite this, GAT has continued in a largel...